Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 11, 2022

SELL
$75.82 - $150.97 $576,232 - $1.15 Million
-7,600 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$132.01 - $190.29 $1 Million - $1.45 Million
7,600 New
7,600 $1.12 Million

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Twin Tree Management, LP Portfolio

Follow Twin Tree Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Twin Tree Management, LP with notifications on news.